危急的COVID-19ICU病例中的持续死亡率从野生型到三角洲变种:描述性队列研究
Lars Palmowski1, André Hagedorn1, Andrea Witowski1
1Klinik Für Anästhesiologie, Intensivmedizin und Schmerztherapie, Universitätsklinikum Knappschaftskrankenhaus Bochum, 44892, Bochum, Germany.
Scientific reports
|March 26, 2025
概括
尽管在COVID-19治疗和疫苗方面取得了进展,但重症监护病房 (ICU) 的重症监护死亡率仍然很高. 这项研究发现,在两次大流行期间,严重病情的COVID-19患者的30天死亡率没有显著下降.
科学领域:
- 密集护理医学 密集护理医学
- 传染性疾病 传染性疾病
- 流行病学 流行病学
背景情况:
- 由于COVID-19的流行,治疗和疫苗接种方面取得了快速进展,从而降低了整体死亡率.
- 然而,这些进展对需要进入重症监护室 (ICU) 的COVID-19危急患者的死亡率的影响仍然不确定.
研究的目的:
- 为了调查30天死亡率和其他重症监护结果是否改善,在流行病的早期和后期阶段之间,在ICU接受严重COVID-19的患者.
- 分析德国和奥地利ICU中COVID-19重症患者的死亡率和发病率的趋势.
主要方法:
- 一项多中心,跨国回顾性观察研究分析了德国和奥地利10个重症监护室的447名COVID-19重症患者.
- 患者被分为两个队列:1期 (2020年3月至2021年5月) 和2期 (2021年6月至2022年1月).
- 关键结局包括30天死亡率,无ICU日,无呼吸器支持日,无血管压缩剂日和无透析日.
主要成果:
- 在第一期 (30%) 和第二期 (37%) 之间,三十天死亡率相似,没有统计学上显著的差异 (HR 1.26,p=0.181).
- 在两段时间之间,没有观察到无ICU日,无呼吸器支持日,无血管压缩剂日或无透析日的显著改善.
- 在第二期的ICU患者中,很大一部分 (81%) 没有接种疫苗,这凸显了他们持续的脆弱性.
结论:
- 尽管治疗策略和疫苗的可用性不断发展,但严重的COVID-19疾病继续与ICU中的30天高且不变的死亡率有关.
- 这些发现强调了严重的COVID-19在ICU环境中的持续致命性.
- 对高风险ICU患者的有针对性的干预措施进行进一步的研究是有必要的,以应对持续的死亡率挑战.
相关概念视频
Viral Mutations
32.1K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.1K
Acute Respiratory Failure-III
147
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
147
Pneumonia IV: Management
280
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
280
Acute Respiratory Failure-IV
115
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
115
Acute Respiratory Failure-V
113
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
113
Pneumonia I: Introduction
201
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
201


